Dr Olivier Marchès, PhD, Fellow of the HEA
Non-Clinical Lecturer in Microbiology
Email: firstname.lastname@example.orgTelephone: 020 7882 2425
Olivier was awarded a PhD in September 2003 from the University Paul Sabatier in Toulouse (France) working on the molecular and cellular basis of pathogenic Escherichia coli virulence in Pr. Eric Oswald’s team (Laboratoire Interactions Hotes-Agents Pathogènes (IHAP)). Olivier was then awarded a Marie Curie Intra-European Fellowship to conduct post-doctoral research in Pr Gad Frankel's lab at Imperial College where he has carried on studies on pathogenic E. coli from December 2003 to September 2007. In October 2007, he has joined the Centre for Immunology and Infectious Disease (now Centre for Immunobiology) within the Blizard Institute (QMUL), where he has been appointed as a Non-Clinical Lecturer in Microbiology. Since 2017, Olivier is a fellow of the Higher Education Academy.
I obtained my PhD in September 2003 from the University Paul Sabatier in Toulouse ( France ) working on molecular and cellular basis of pathogenic Escherichia coli virulence in the team of Dr Eric Oswald (Laboratoire Interactions Hotes-Agents Pathogènes (IHAP)). Then I was awarded a Marie Curie fellowship to conduct post-doctoral research in Pr Gad Frankel's lab at the Imperial College where I have carried on my studies on pathogenic E. coli from December 2003 to September 2007. Since October 2007, I have joined the Centre for Immunology and Infectious Disease within the Blizard Institute, where I have been appointed as a Non-Clinical Lecturer in Bacteriology.
Module lead for 2nd year BSc module Infection, immunology & Inflammation” – BMD269
Module lead for MSc Clinical Microbiology module “Molecular biology pathogenesis and Immunology – ICM7093
Immunobiology Centre Education lead for Undergraduate studies
Teaching on BSc modules (Biomedical sciences, Pharmacology & Innovative Therapeutics and Neurosciences):
Humans (lectures) BMD117
Clinical Microbiology (lecture and practical) BMD231
Infection, Immunity & Inflammation (lectures & tutorials) BMD269
Biomedical Science case approach to problem solving (tutorials) BMD301
Infectious diseases (lectures & workshops) BMD323
Project skill in the life science (library research project supervisor) BIO603
Teaching for Postgraduate for MSc Infection Science, Clinical and Medical Microbiology:
Molecular biology, microbial pathogenesis & immunology (lectures & workshops)
Library based research projects (supervisor)
Teaching for undergraduate medical students – MBBS:
Fundamentals of Medicine (lectures)
Problem based learning (facilitator)
Student selected component – year 2 (literature project supervisor)
Enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) Escherichia coli are important causes of acute gastroenteritis in humans. EPEC is a frequent cause of infantile diarrhoea in the developing world while EHEC causes a wide spectrum of illnesses ranging from mild diarrhoea to severe diseases, such as haemorrhagic colitis and haemolytic uraemic syndrome (HUS). Olivier’s main research interest has been to decipher the molecular cross-talk established between the EPEC or EHEC bacteria and their host with a long term aim being to identify new tracks to follow for development of therapeutics or control strategies for infections. A key element in EPEC and EHEC pathogenic strategy is their use of a type 3 secretion system to inject virulence proteins called effectors directly into host eukaryotic cells, proteins that subvert normal cellular functions. The main interest is to study the function of the effectors injected into the host tissues by pathogenic E. coli and the cellular pathways they subvert with a focus on the effectors used by the bacteria to manipulate mucosal immunity.
Brooke MA, Etheridge SL, Kaplan N, Simpson C, O'Toole EA, Ishida-Yamamoto A, Marchès O, Getsios S, Kelsell DP. iRhom2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function Hum. Mol Genet. 2014 Mar 28.
Pearson JS, Giogha C, Ong SY, Kennedy CL, Kelly M, Robinson KS, Lung TW, Mansell A, Riedmaier P, Oates CV, Zaid A, Mühlen S, Crepin VF, Marchès O, Ang CS, Williamson NA, O'Reilly LA, Bankovacki A, Nachbur U, Infusini G, Webb AI, Silke J, Strasser A, Frankel G, Hartland ELA type III effector antagonizes death receptor signalling during bacterial gut infection. Nature. 2013 Sep 12;501(7466):247-51.
Simpson C, Kelsell DP, Marchès O. Connexin 26 facilitates gastrointestinal bacterial infection in vitro. Cell Tissue Res. 2013; Jan;351(1):107-16.
Pearson, J.S., Riedmaier, P., Marchès, O., Frankel, G. & Hartland, E.L. A type III effector proteas NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol 2011; 80, 219-230.
Marchès O., Vossenkämper A, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong le A, Croft NM, Naik S, Frankel G, MacDonald TT. Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol 2010; 185, 4118-4127.
Vossenkämper A, Macdonald TT, Marchès O Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system. J Inflamm (Lond),2011 8:11.
View all Olivier Marchès's Research Publications at: http://www.researchpublications.qmul.ac.uk